#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Czech Rheumatology / 2023 - 3

Pain in axial spondyloarthritis – causes, evaluation, differential diagnosis and therapy options

Czech version

Authors: L. Procházková
Authors‘ workplace: Revmatologie, II. interní klinika FN u sv. Anny a LF MU, Brno
Published in: Čes. Revmatol., 31, 2023, No. 3, p. 122-129.
Category: Reviews

Overview

 

Pain is one of the basic manifestations of most rheumatic diseases in general, from the patients' point of view it is one of the most important symptoms affecting the quality of life. In axial spondyloarthritis, one of the basic clinical characteristics is back pain. In this context, we usually talk about inflammatory back pain, which has its specific characteristics. However, pain in these patients can be conditioned by many other factors, such as degenerative changes in the spine, vertebral fractures resulting from osteoporosis, or concomitant fibromyalgia in patients with central pain sensitization. However, the issue is that the assessment of disease activity and the effect of therapy is based, among other things, on the assessment of the effect on the pain. It is therefore obvious that in the case of a different etiology of pain, the assessment of the effect of the therapy may be adversely affected and may lead to an unnecessary escalation of anti-inflammatory therapy, without an effect on the pain itself.

 

Keywords:

Pain – axial spondyloarthritis – inflammatory back pain – residual pain

Sources
  1. Lampa J. Pain without inflammation in rheumatic diseases. Best Pract Res Clin Rheumatol 2019; 33(3): 101439.
  2. Kiltz U, Baraliakos X, Regel A, et al. Causes of pain in patients with axial spondyloarthritis. Clin Exp Rheumatol 2017; 107(5 Suppl): 102–107.
  3. Moltó A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 2016; 75(6): 1016–1023.
  4. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain 2020; 161(9): 1976–1982.
  5. Kozák J. Bolest a její nová definice. Medicína po promoci 2020; 21(3): 185–189.
  6. Sieper J, van der Heijde D, Landewé R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS) Ann Rheum Dis 2009; 68: 784–788.
  7. Rudwaleit M, Landewé R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68: 770–776.
  8. de Hooge M, Bruin F, Beer L, et al. Is the site of back pain related to the location of magnetic resonance imaging lesions in patients with chronic back pain? Results from the spondyloarthritis caught early cohort. Arthritis Care Res (Hoboken) 2017; 69: 717–723.
  9. de Bruin F, Treyvaud MO, Feydy A, et al. Prevalence of degenerative changes and overlap with spondyloarthritis-associated lesions in the spine of patients from the DESIR cohort. RMD Open 2018; 4: e000657.
  10. Khan MA, van der Linden S. Ankylosing spondylitis: clinical aspects. In: SPINE: state of the art reviews. Philadelphia: Hanley & Belfus 1990; 529–555.
  11. Fitzgerald GE, O’Shea FD. The fascinating paradox of osteoporosis in axial spondyloarthropathy. J Rheumatol 2017; 44: 1767– 1776. 10.3899/jrheum.170051
  12. Pavelka K, Dejmková H, Štolfa J. Spondyloartritidy. In: Pavelka K, et al. Revmatologie. Praha: Maxdorf 2018; 368–393.
  13. Chaudhary SB, Hullinger H, Vives MJ. Management of acute spinal fractures in ankylosing spondylitis. ISRN Rheumatol 2011; 2011: 150484.
  14. Ramírez J, Nieto-González JC, Curbelo Rodríguez R, et al. Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. Semin Arthritis Rheum 2018; 48(1): 44–52.
  1. Mandl P, Navarro-Compán V, Terslev L, et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis 2015; 74: 1327–1339.
  2. Gao R. Effects of fibromyalgia on the disease activity and treatment of patients with axial spondyloarthritis. J Musculoskelet Neuronal Interact 2021; 21: 440–446.
  3. Swinnen TW, Westhovens R, Dankaerts W, et al. Widespread pain in axial spondyloarthritis: clinical importance and gender differences. Arthritis Res Ther 2018; 20: 1–11.
  4. Kieskamp SC, Paap D, Carbo MJG et al. Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis. Rheumatology (Oxford) 2021; 60: 4476–4485.
  5. Jones GT, Mallawaarachchi B, Shim J, et al. The prevalence of fibromyalgia in axial spondyloarthritis. Rheumatol Int 2020; 40(10): 1581–1591.
  6. Mease PJ, Liu M, Rebello S, et al. Characterization of patients with axial spondyloarthritis by enthesitis presence: data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatol 2020; 2: 449–456.
  7. Freynhagen R, Baron R, Gockel U, et al. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22(10): 1911– 1920.
  8. Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011; 70(1): 47–53.
  9. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008: 2008(1): CD002822.
  10. Webers C, Ortolan A, Sepriano A, et al. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis 2023; 82: 130–141.
  11. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2023; 82(1): 19–34.
  12. Sepriano A, Regel A, van der Heijde D, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 2017; 3(1): e000396.
  13. Callhoff J, Sieper J, Weiss A, et al. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2015; 74: 1241–1248.
  14. Machado MA, Barbosa MM, Almeida AM, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 2013; 33: 2199–2213.
  15. Ørnbjerg LM, Rugbjerg K, Georgiadis S, et al. One-third of European patients with axial spondyloarthritis reach pain remission with routine care tumor necrosis factor inhibitor treatment. J Rheumatol 2022. jrheum.220459
  1. Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017; 76: 1070–1077.
  2. Poddubnyy D, Pournara E, Zielińska A, et al. Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial. Ther Adv Musculoskelet Dis 2021; 13: 1759720X211051471.
  3. Deodhar AA, Mease PJ, Rahman P, et al. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial spondyloarthritis: COAST-V/W 52-week results. BMC Rheumatol 2021; 5(1): 35.
  4. Jiang X, Zhou R, Zhang Y, et al. Interleukin-17 as a potential therapeutic target for chronic pain. Front Immunol 2022; 13: 999407.
  5. Deodhar A, Conaghan PG, Kvien TK, et al. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clin Exp Rheumatol 2019; 37(2): 260–269.
  6. Deodhar A, van der Heijde D, Sieper J, et al. Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension. Arthritis Rheumatol 2022; 74(1): 70–80.
  7. Navarro-Compán V, Wei JC, Van den Bosch F, et al. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open 2022; 8(2): e002253.
  8. Simon LS, Taylor PC, Choy EH, et al. The JAK/STAT pathway: a focus on pain in rheumatoid arthritis. Semin Arthritis Rheum 2021; 51: 278–284.
  9. Crispino N, Ciccia F. Jak/Stat pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 2021; 39: 668–675.
  10. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia Ann Rheum Dis 2017; 76: 318–328.
  11. Calin A, Porta J, Fries JF, et al. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977; 237(24): 2613–2614.
  12. Rudwaleit M, Metter A, Listing J, et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006; 54(2): 569–578.
  13. Sieper J, van der Heijde D, Landewé R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009; 68(6): 784–788.
  14. Caplan I. Axial spondyloarthritis. In: Sterling, GW, Ed. Rheumatology Secrets, 4th ed. Philadelphia: Elsevier; 284–290.
Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Quo vadis dětská revmatologie?
The anniversary of chief radiologist Jindra Gatterová
Pregnancy issues in rheumatic diseases
Septic arthritis in light of the guidelines of the French Society for Rheumatology
Long-term outcomes of ixekizumab treatment in patients with axial spondyloarthritis
Complications and comorbidities in established psoriatic arthritis patient – case report
INSTRUCTIONS TO THE AUTHORS
Article was published in

Czech Rheumatology

Issue 3
2023 Issue 3
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#